Small cell carcinoma of the urinary bladder without gross hematuria: a case report

doi:10.1007/s11684-015-0405-z

Front. Med.

2015, Vol. 9

Issue (3) : 384-387 https://doi.org/10.1007/s11684-015-0405-z

CASE REPORT

Small cell carcinoma of the urinary bladder without gross hematuria: a case report

Wanqiu Huang^1,²,Yang Luan¹,Lu Jin¹,Tao Wang¹,Ruibao Chen¹,Zheng Liu¹,Zhiqiang Chen¹,Ruzhu Lan^1,^*(

)

1. Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
2. Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

Download: PDF(535 KB) HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract

Small cell carcinoma of the urinary bladder (SCCB) is a rare and aggressive form of bladder cancer with poor prognosis. Hematuria is the main symptom of this malignancy, and most patients have a history of smoking. The disease incidence of malignant bladder tumors in China is approximately 0.74%. Early and accurate diagnosis of SCCB can ensure timely and appropriate treatment of this malignant disease. Oncologic surgery is the standard treatment; however, it may not be a curative approach. Chemotherapy and/or radiotherapy should be performed following surgical removal. This case report describes a patient with a single neoplasm diagnosed as SCCB that arose because of recurrence of bladder cancer after bladder tumor resection. In contrast to previously reported cases, this patient had no gross hematuria and no history of smoking.

Keywords carcinoma small cell urinary bladder neoplasms diagnosis

Corresponding Author(s): Ruzhu Lan

Just Accepted Date: 08 July 2015 Online First Date: 11 August 2015 Issue Date: 26 August 2015

Cite this article:

Wanqiu Huang,Yang Luan,Lu Jin, et al. Small cell carcinoma of the urinary bladder without gross hematuria: a case report[J]. Front. Med., 2015, 9(3): 384-387.

URL:

https://academic.hep.com.cn/fmd/EN/10.1007/s11684-015-0405-z
https://academic.hep.com.cn/fmd/EN/Y2015/V9/I3/384

Fig.1 (A) CT scan showing a papillomatous mass arising from the back wall of the bladder. (B) A portion of the bladder tissue was resected, which contained an exogenous mass (3 cm × 2 cm in size) adhering to the adjacent peritoneum.

Fig.2 (A) H&E stain of the tumor. Immunohistochemical staining revealed that the tumor cells were positive for EMA (B), CD56 (C), CK-PAN (D), and SYN (E), but negative for CK20 (F), CD45 (G), and CgA (H) (200×).

1	Cheng L, Pan CX, Yang XJ, Lopez-Beltran A, MacLennan GT, Lin H, Kuzel TM, Papavero V, Tretiakova M, Nigro K, Koch MO, Eble JN. Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Cancer 2004; 101(5): 957–962 https://doi.org/10.1002/cncr.20456 pmid: 15329903
2	Trias I, Algaba F, Condom E, Espa?ol I, Seguí J, Orsola I, Villavicencio H, García Del Muro X. Small cell carcinoma of the urinary bladder. Presentation of 23 cases and review of 134 published cases. Eur Urol 2001; 39(1): 85–90 https://doi.org/10.1159/000052417 pmid: 11173944
3	Cramer SF, Aikawa M, Cebelin M. Neurosecretory granules in small cell invasive carcinoma of the urinary bladder. Cancer 1981; 47(4): 724–730 https://doi.org/10.1002/1097-0142(19810215)47:4<724::AID-CNCR2820470417>3.0.CO;2-2 pmid: 6261916
4	Blomjous CE, Vos W, De Voogt HJ, Van der Valk P, Meijer CJ. Small cell carcinoma of the urinary bladder. A clinicopathologic, morphometric, immunohistochemical, and ultrastructural study of 18 cases. Cancer 1989; 64(6): 1347–1357 https://doi.org/10.1002/1097-0142(19890915)64:6<1347::AID-CNCR2820640629>3.0.CO;2-Q pmid: 2548704
5	Choong NW, Quevedo JF, Kaur JS. Small cell carcinoma of the urinary bladder. The Mayo Clinic experience. Cancer 2005; 103(6): 1172–1178 https://doi.org/10.1002/cncr.20903 pmid: 15700264
6	Hou CP, Lin YH, Chen CL, Chang PL, Tsui KH. Clinical outcome of primary small cell carcinoma of the urinary bladder. Onco Targets Ther 2013; 6: 1179–1185 pmid: 24009428
7	Sved P, Gomez P, Manoharan M, Civantos F, Soloway MS. Small cell carcinoma of the bladder. BJU Int 2004; 94(1): 12–17 https://doi.org/10.1111/j.1464-410X.2003.04893.x pmid: 15217423
8	Ismaili N, Elkarak F, Heudel PE, Flechon A, Droz JP. Small cell cancer of the bladder: The Leon-Berard cancer centre experience. Indian J Urol 2008; 24(4): 494–497 https://doi.org/10.4103/0970-1591.44255 pmid: 19468504
9	Siefker-Radtke AO, Dinney CP, Abrahams NA, Moran C, Shen Y, Pisters LL, Grossman HB, Swanson DA, Millikan RE. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J Urol 2004; 172(2): 481–484 https://doi.org/10.1097/01.ju.0000132413.85866.fc pmid: 15247709
10	Lohrisch C, Murray N, Pickles T, Sullivan L. Small cell carcinoma of the bladder: long term outcome with integrated chemoradiation. Cancer 1999; 86(11): 2346–2352 https://doi.org/10.1002/(SICI)1097-0142(19991201)86:11<2346::AID-CNCR24>3.0.CO;2-5 pmid: 10590377
11	Reyes CV, Soneru I. Small cell carcinoma of the urinary bladder with hypercalcemia. Cancer 1985; 56(10): 2530–2533 https://doi.org/10.1002/1097-0142(19851115)56:10<2530::AID-CNCR2820561035>3.0.CO;2-4 pmid: 2994881
12	Gon S, Majumdar B, Dey RK, Mitra SK. Pure primary small cell carcinoma of urinary bladder: a rare diagnostic entity. Urol Ann 2013; 5(3): 209–211 https://doi.org/10.4103/0974-7796.115751 pmid: 24049389
13	Epstein JI, Amin MB, Reuter VE. Bladder biopsy interpretation. MA: Lippincott Williams and Wilkins 2004: 126–128
14	Jones TD, Kernek KM, Yang XJ, Lopez-Beltran A, MacLennan GT, Eble JN, Lin H, Pan CX, Tretiakova M, Baldridge LA, Cheng L. Thyroid transcription factor 1 expression in small cell carcinoma of the urinary bladder: an immunohistochemical profile of 44 cases. Hum Pathol 2005; 36(7): 718–723 https://doi.org/10.1016/j.humpath.2005.04.007 pmid: 16084939
15	Soriano P, Navarro S, Gil M, Llombart-Bosch A. Small-cell carcinoma of the urinary bladder. A clinico-pathological study of ten cases. Virchows Arch 2004; 445(3): 292–297 https://doi.org/10.1007/s00428-004-1041-1 pmid: 15248064
16	Karpman E, Goldberg Z, Saffarian A, Gandour-Edwards R, Ellison LM, deVere White RW. Analysis of treatment for small cell cancer of the bladder and report of three cases. Urology 2004; 64(3): 494–498 https://doi.org/10.1016/j.urology.2004.04.038 pmid: 15351578
17	Iczkowski KA, Shanks JH, Bostwick DG. Loss of CD44 variant 6 expression differentiates small cell carcinoma of urinary bladder from urothelial (transitional cell) carcinoma. Histopathology 1998; 32(4): 322–327 https://doi.org/10.1046/j.1365-2559.1998.00398.x pmid: 9602328
18	Alijo Serrano F, Sánchez-Mora N, Angel Arranz J, Hernández C, Alvarez-Fernández E. Large cell and small cell neuroendocrine bladder carcinoma: immunohistochemical and outcome study in a single institution. Am J Clin Pathol 2007; 128(5): 733–739 https://doi.org/10.1309/HTREM6QYQDYGNWYA
19	Church DN, Bahl A. Clinical review—<?Pub Caret?>small cell carcinoma of the bladder. Cancer Treat Rev 2006; 32(8): 588–593 https://doi.org/10.1016/j.ctrv.2006.07.013 pmid: 17008012
20	Dahm P, Gschwend JE. Malignant non-urothelial neoplasms of the urinary bladder: a review. Eur Urol 2003; 44(6): 672–681 https://doi.org/10.1016/S0302-2838(03)00416-0 pmid: 14644119
21	Abrahams NA, Moran C, Reyes AO, Siefker-Radtke A, Ayala AG. Small cell carcinoma of the bladder: a contemporary clinicopathological study of 51 cases. Histopathology 2005; 46(1): 57–63 https://doi.org/10.1111/j.1365-2559.2004.01980.x pmid: 15656887

[1]	Dongping Ning, Zhan Zhang, Kun Qiu, Lin Lu, Qin Zhang, Yan Zhu, Renzhi Wang. Efficacy of intelligent diagnosis with a dynamic uncertain causality graph model for rare disorders of sex development[J]. Front. Med., 2020, 14(4): 498-505.
[2]	Yang Jiao, Zhan Zhang, Ting Zhang, Wen Shi, Yan Zhu, Jie Hu, Qin Zhang. Development of an artificial intelligence diagnostic model based on dynamic uncertain causality graph for the differential diagnosis of dyspnea[J]. Front. Med., 2020, 14(4): 488-497.
[3]	Amy Lee, Fa-Chyi Lee. Medical oncology management of advanced hepatocellular carcinoma 2019: a reality check[J]. Front. Med., 2020, 14(3): 273-283.
[4]	Yue Wang, Jinxia Zhang, Yunfan Wang, Shufang Wang, Yu Zhang, Qi Miao, Fei Gao, Huiying He. Expression status of GATA3 and mismatch repair proteins in upper tract urothelial carcinoma[J]. Front. Med., 2019, 13(6): 730-740.
[5]	Hanyu Zhu, Bo Fu, Yong Wang, Jing Gao, Qiuxia Han, Wenjia Geng, Xiaoli Yang, Guangyan Cai, Xiangmei Chen, Dong Zhang. Comparative analysis of membranous and other nephropathy subtypes and establishment of a diagnostic model[J]. Front. Med., 2019, 13(5): 618-625.
[6]	Xiaolin Fan, Yanzhen Xiong, Yuan Wang. A reignited debate over the cell(s) of origin for glioblastoma and its clinical implications[J]. Front. Med., 2019, 13(5): 531-539.
[7]	Wenjing Wang, Shigang Ding, Hejun Zhang, Jun Li, Jun Zhan, Hongquan Zhang. G protein-coupled receptor LGR6 is an independent risk factor for colon adenocarcinoma[J]. Front. Med., 2019, 13(4): 482-491.
[8]	Min Zhang, Jingwen Yang, Wenjing Hua, Zhong Li, Zenghui Xu, Qijun Qian. Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy[J]. Front. Med., 2019, 13(1): 32-44.
[9]	Renyu Zhang, Zhao Zhang, Zekun Liu, Ding Wei, Xiaodong Wu, Huijie Bian, Zhinan Chen. Adoptive cell transfer therapy for hepatocellular carcinoma[J]. Front. Med., 2019, 13(1): 3-11.
[10]	Liru Qiu, Fengjie Yang, Yonghua He, Huiqing Yuan, Jianhua Zhou. Clinical characterization and diagnosis of cystic fibrosis through exome sequencing in Chinese infants with Bartter-syndrome-like hypokalemia alkalosis[J]. Front. Med., 2018, 12(5): 550-558.
[11]	Lan Yu, Xun Tian, Chun Gao, Ping Wu, Liming Wang, Bei Feng, Xiaomin Li, Hui Wang, Ding Ma, Zheng Hu. Genome editing for the treatment of tumorigenic viral infections and virus-related carcinomas[J]. Front. Med., 2018, 12(5): 497-508.
[12]	Xinxin Xu, Yinshi Guo, Qiuying Li, Ling Yang, Jianqiang Kang. Invasive mucinous adenocarcinoma with lepidic-predominant pattern coexisted with tuberculosis: a case report[J]. Front. Med., 2018, 12(3): 330-333.
[13]	Shasha Zhu, Huimin Zhang, Li Bai. NKT cells in liver diseases[J]. Front. Med., 2018, 12(3): 249-261.
[14]	Guangbiao Zhou, Xinchun Zhao. Carcinogens that induce the A:T>T:A nucleotide substitutions in the genome[J]. Front. Med., 2018, 12(2): 236-238.
[15]	Min Yu, Zonghai Li. Natural killer cells in hepatocellular carcinoma: current status and perspectives for future immunotherapeutic approaches[J]. Front. Med., 2017, 11(4): 509-521.

Viewed

Full text

Abstract

Cited

Shared

Discussed